Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 15;23(16):5182-9.
doi: 10.1016/j.bmc.2015.02.020. Epub 2015 Feb 18.

SAR Refinement of Antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines

Affiliations
Free PMC article

SAR Refinement of Antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines

Xiaohua Zhu et al. Bioorg Med Chem. .
Free PMC article

Abstract

Visceral leishmaniasis is a neglected parasitic disease that has a high fatality rate in the absence of treatment. New drugs that are inexpensive, orally active, and effective could be useful tools in the fight against this disease. We previously showed that N(2),N(4)-disubstituted quinazoline-2,4-diamines displayed low- to sub-micromolar potency against intracellular Leishmania, and lead compound N(4)-(furan-2-ylmethyl)-N(2)-isopropyl-7-methylquinazoline-2,4-diamine (4) exhibited modest efficacy in an acute murine model of visceral leishmaniasis. In the present work, thirty-one N(2),N(4)-disubstituted quinazoline-2,4-diamines that had not previously been examined for their antileishmanial activity were evaluated for their potency and selectivity against Leishmania donovani, the causative parasite of visceral leishmaniasis. Quinazoline-2,4-diamines with aromatic substituents at both N(2) and N(4) exhibited potent in vitro antileishmanial activity but relatively low selectivity, while compounds substituted with small alkyl groups at either N(2) or N(4) generally showed lower antileishmanial potency but were less toxic to a murine macrophage cell line. Based on their in vitro antileishmanial potency, N(4)-benzyl-N(2)-(4-chlorobenzyl)quinazoline-2,4-diamine (15) and N(2)-benzyl-N(4)-isopropylquinazoline-2,4-diamine (40) were selected for in vivo evaluation of their pharmacokinetic and antileishmanial properties. While 15 displayed a longer plasma half-life and a greater area under the curve than 40, both compounds showed low efficacy in an acute murine visceral leishmaniasis model. Although the present study did not identify new quinazoline-2,4-diamines with promising in vivo efficacy, the reduced in vitro toxicity of derivatives bearing small alkyl groups at either N(2) or N(4) may provide clues for the design of safe and effective antileishmanial quinazolines.

Keywords: Leishmania; Neglected disease; Parasitic disease; Quinazoline.

Figures

Figure 1
Figure 1
N2,N4-Disubstituted quinazoline diamines 14 with potent antileishmanial activity.
Figure 2
Figure 2
Mean plasma (○), liver (■), and spleen (▲) concentration–time profiles of compound 15 (A) and compound 40 (B) after ip administration at a dose of 10 mg/ kg to mice. Symbols and error bars represent the mean and standard error of triplicate determinations.
Scheme 1
Scheme 1
Synthetic routes for the preparation of antileishmanial quinazolines.

Similar articles

See all similar articles

Cited by 5 articles

Publication types

MeSH terms

LinkOut - more resources

Feedback